Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2025)
Karyopharm Therapeutics (KPTI) reported Total Debt of $115.8 million for Q4 2025, up 22.41% on a YoY basis from $94.6 million in Q4 2024, and up 20.14% quarter-over-quarter from $96.4 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Total Debt (2024 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Total Debt for 2 years, with the latest figure at $115.8 million in Q4 2025.
- For the quarter ending Q4 2025, Total Debt rose 22.41% year-over-year to $115.8 million; the trailing twelve-month figure through Dec 2025 stood at $115.8 million (up 22.41% YoY), and the FY2025 full-year result was $115.8 million, up 22.41% from the prior year.
- Total Debt for Q4 2025 stood at $115.8 million, up from $96.4 million in the prior quarter.
- The five-year high for Total Debt was $115.8 million in Q4 2025, with the low at $93.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 115.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115.81 Mn |
| Sep 30, 2025 | 96.40 Mn |
| Jun 30, 2025 | 95.82 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 94.60 Mn |
| Sep 30, 2024 | 94.11 Mn |
| Jun 30, 2024 | 93.52 Mn |